Cellerant Raising Series B

Cellerant Therapeutics Inc., a Palo Alto, Calif.-based developer of blood-forming stem cell-based therapies for cancer, genetic blood disorders and autoimmune diseases, has secured $4.4 million of a $5 million Series B round, according to a regulatory filing. Backers include Camelot Ventures and MPM Capital. www.cellerant.com